Your browser doesn't support javascript.
loading
Pilot study of a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant.
Clure, Cara; Sheeder, Jeanelle; Lazorwitz, Aaron.
Afiliación
  • Clure C; Division of Complex Family Planning, Department of Obstetrics and Gynecology, University of Colorado Anschutz Medical Campus, Aurora, CO, United States. Electronic address: Cara.clure@cuanschutz.edu.
  • Sheeder J; Division of Complex Family Planning, Department of Obstetrics and Gynecology, University of Colorado Anschutz Medical Campus, Aurora, CO, United States. Electronic address: Jeanelle.sheeder@cuanschutz.edu.
  • Lazorwitz A; Division of Complex Family Planning, Department of Obstetrics, Gynecology, & Reproductive Sciences, Yale School of Medicine, New Haven, CT, United States. Electronic address: Aaron.lazorwitz@yale.edu.
Contraception ; 135: 110442, 2024 Jul.
Article en En | MEDLINE | ID: mdl-38552822
ABSTRACT

OBJECTIVES:

To assess the pharmacokinetics and pharmacodynamics of the etonogestrel (ENG) contraceptive implant when inserted at an alternative scapular site. STUDY

DESIGN:

We conducted a pilot study of healthy, reproductive-age females who underwent subdermal insertion of an ENG implant over the inferior edge of the nondominant scapula (scapular insertion). We measured serum ENG levels over 1 year at nine time points. Participants completed questionnaires on insertion site and bleeding side effects. We collected photographs and video recordings of insertion and removal techniques.

RESULTS:

We enrolled five participants (as prespecified), their median age was 26.0 years (range 19.6-30.3), and median body mass index was 25.0 kg/m2 (range 22.0-28.0). All serum ENG concentrations remained >90 pg/mL and were within the range of published data for arm insertion of ENG implant at all time points. The mean serum ENG level was 511.7 pg/mL (±168.2) at 1 week and 136.6 pg/mL (±21.8) at 12 months. During the first week after insertion, four of five participants noted insertion site pain with a median pain score of 2 (range 1-3), but all noted resolution by week two. Participants reported variable bleeding patterns consistent with standard ENG implant placement. At the end of the study, all participants reported satisfaction with the implant and would recommend scapular insertion to a friend.

CONCLUSIONS:

Scapular insertion of the ENG contraceptive implant has similar pharmacokinetics to arm insertion over 1 year of use. This novel, alternative site was well tolerated and demonstrated similar bleeding side effects to standard arm insertion. IMPLICATIONS Subdermal scapular insertion of the etonogestrel contraceptive implant demonstrated similar pharmacokinetics to arm insertion over 1 year of use. Our pilot data support scapular insertion as an alternative site for ENG contraceptive implants, which could be beneficial for certain patient populations.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Escápula / Desogestrel / Anticonceptivos Femeninos / Implantes de Medicamentos Límite: Adult / Female / Humans Idioma: En Revista: Contraception Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Escápula / Desogestrel / Anticonceptivos Femeninos / Implantes de Medicamentos Límite: Adult / Female / Humans Idioma: En Revista: Contraception Año: 2024 Tipo del documento: Article